Blog

This is tagline here

Begbroke Science Park > News and Press > Zyoxel In Line For Most Promising Young Spin-out
Please set your featured image

Zyoxel In Line For Most Promising Young Spin-out

zyoxel picture

Zyoxel, an innovative spin-out company from the University of Oxford, based at Begbroke Science Park, is one of 15 finalists nominated from the whole of Europe for the ACES Academic Enterprise Awards. The ACES is the only pan-European programme to recognise entrepreneurship in academic institutions. The award is given to the company who in the judge’s opinion has the greatest potential for commercial success and impact on society.

Zyoxel, launched in July 2009, provides services to the pharmaceutical, chemical testing and cell culture markets to develop specific testing applications.

Professor Peter Dobson, the Director of Oxford University’s Begbroke Science Park explains, “Professor Zhanfeng Cui’s group from the Institute of Biomedical Engineering in Oxford University has developed several applications using their platform technology – TissueFlex® microbioreactors which is central to Zyoxel’s business. These microbioreactors have the potential to revolutionize many stem cell studies, drug screening and artificial scaffold ideas, in a compact and affordable form and provide a good example of the very active translational and high impact activities in the University that start at the Begbroke Science Park”.

Zyoxel’s success illustrates how much can be achieved by a young spin-out company in a short time. Tim Hart, CEO, comments “I am delighted that Zyoxel has been recognised as one of Europe’s 15 hottest university spin-out companies’. Thanks to the strong technology background and first class team within the company, we have made a flying start and are realising opportunities for the business above and beyond our expectations at launch”

Zyoxel is just one of around 30 spin-out and start-up companies at Begbroke Science Park that benefit from its unique interdisciplinary and entrepreneurial environment.



For more information about Zyoxel please visit www.zyoxel.com

Ben Roeves